Brian Arciola

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni et al. · Journal for ImmunoTherapy of Cancer · 2022 · 191 citations · Full text

Medicine, Hematology, Immunology +17

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Veit Bücklein, Ariel Perez Perez, Kai Rejeski et al. · HemaSphere · 2023 · 35 citations · Full text

Medicine, Hematology, Oncology +17

Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

Anthony C. Wood, Ariel Perez Perez, Brian Arciola et al. · Transplantation and Cellular Therapy · 2022 · 31 citations · Full text

Medicine, Immunology, Nephrology +11

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Veit Buecklein, Kai Rejeski, Ariel Perez Perez et al. · Blood · 2023 · 12 citations

Medicine, Immunology, Oncology +16